Balance Medical reports strong H1 growth, revenue up 30%

Balance Medical Technology (688198) reported a strong financial performance in the first half of 2025, with operating revenue surging by 30.07% to yuan 248,028,217.88 and net profit attributable to shareholders rising by 102.90% to yuan 71,400,619.61 compared to the previous year. The company emphasized its commitment to innovation, with several in-development products, including the Renato transcatheter heart valve system, progressing through regulatory approvals and clinical trials. Research and development investment comprised 29.89% of operating revenue.

In parallel with its financial success, Balance Medical advanced its "Quality and Efficiency Enhancement, High Returns" action plan. Key initiatives included a 2024 dividend distribution of yuan 0.80 per share, totaling yuan 109,916,118.40, and shareholding increases by its controlling shareholder. The company also implemented several governance reforms, including revisions to its Related Party Transactions Management System, Profit Distribution Management System, and Rules of Conduct for Controlling Shareholders and Actual Controllers, which were approved at the Third Board of Directors’ Eleventh Meeting on August 27, 2025.

These governance updates, effective upon shareholder approval, aim to enhance transparency, protect shareholder interests, and ensure compliance. The comprehensive set of revised policies underscores the company's focus on maintaining high standards of corporate governance and continuous improvement in operational efficiency.